Direct oral anticoagulants in patients with chronic kidney disease: patient selection and special considerations.

Int J Nephrol Renovasc Dis · 2017 · PMC5473496 · PMID 28652799

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Treatment with rivaroxaban showed a trend toward improved safety in patients aged >75 years, according to the EINSTEIN trials. 62 Edoxaban had a trend toward higher efficacy in this patient group in the HOKUSAI-VTE trial, while its safety was not affected by age. 51 Data regarding age and renal function in both trials are not available so far.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.